Loading clinical trials...

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy

NCT00632385•Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

View on ClinicalTrials.gov

Summary

To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of migraine headache according to International Headache Society criteria and migraine headaches for at least 1 year
•Eletriptan naive
•Previously treated with rizatriptan and failed to achieve a satisfactory response within the past 12 months

Exclusion Criteria

•Non-migraine headaches on average more than 6 days per month or have less than 24 hours of freedom from headache between migraine attacks
•Migraine attacks that are atypical or chronic daily headaches
•A history of migraine with prolonged aura, familial hemiplegic migraine, basilar migraine, migrainous infarction, migraine aura without headache, migraine with acute onset aura

Locations (16)

Pfizer Investigational Site

Irvine, California, United States

Pfizer Investigational Site

Newport Beach, California, United States

Pfizer Investigational Site

San Francisco, California, United States

Pfizer Investigational Site

Plantation, Florida, United States

Pfizer Investigational Site

St. Petersburg, Florida, United States

Pfizer Investigational Site

Tampa, Florida, United States

Pfizer Investigational Site

Marietta, Georgia, United States

Pfizer Investigational Site

South Bend, Indiana, United States

Pfizer Investigational Site

Milford, Massachusetts, United States

Pfizer Investigational Site

Chesterfield, Missouri, United States

Key Dates

Start Date

January 1, 2003

Completion Date

August 1, 2003

Last Updated

January 27, 2021

Enrollment

127

ACTUAL participants

Conditions

Migraine

Interventions

Eletriptan

DRUG

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713

Chronic Migraine

View study

RECRUITINGPHASE3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466

Menstrual Migraine

View study

RECRUITINGNA

Mind Body Balance for Pediatric Migraine

NCT04715685

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Mind Body Balance for Pediatric Migraine

Light Exposure, Migraine Outcomes, and Sleep Quality

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Prophylactic Treatment With Atorvastatin for Episodic Migraine.